Drug intelligence / Profile preview

MN-246

Development stage: Discontinued
Lead developer: MediciNova
Modality: Small Molecules

Overview

MN-246 is a small molecule β3-adrenergic receptor agonist that was originally developed by Mitsubishi Tanabe Pharma Corp. Beta-3 adrenergic receptor agonists are a class of drugs that target receptors primarily located in adipose tissue and the bladder detrusor muscle. These agents are typically investigated for the treatment of overactive bladder (OAB), where they promote bladder storage by inducing detrusor relaxation, as well as for obesity and metabolic disorders due to their potential to stimulate lipolysis and thermogenesis. The development of MN-246 has been discontinued globally.

Targets

ADRB3 (β3)

Beyond the preview

Go deeper on MN-246.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MN-246.

Explore the full profile